DNase1L3的活性检测及其临床初步观察

The activity detection and preliminary clinical observation of DNase1L3

DNA酶1样分子3(deoxyribonuclease 1 like 3,DNase1L3)在SLE发病机制中起重要的保护作用,但目前尚缺乏活性良好的DNase1L3蛋白,为了获得有良好活性的DNase1L3并观察DNase1L3的临床价值,克隆DNase1L3分子,并筛选出稳定表达有良好活性DNase1L3的真核细胞株,选择80例SLE患者为SLE组,34例健康志愿者为对照组,检测对照组及SLE组血清DNase1L3的活性水平,同时分析SLE患者血清DNase1L3活性水平与临床指标的相关性。结果显示,SLE组患者血清DNase1L3的活性水平[(97.94±0.19)%]显著低于对照组[(98.91±0.09)%,P<0.05];虽然血清DNase1L3活性与抗核小体抗体和抗dsDNA抗体水平没有显著关联,但在DNase1L3活性<98%的患者群体中,DNase1L3活性与抗核小体抗体水平呈显著负相关(r=-0.4931,P=0.0123)。提示DNase1L3活性水平与SLE的疾病活动性相关,且在SLE发病机制中发挥潜在的保护作用。

Deoxyribonuclease 1 like 3(DNase1L3)plays a protective role in the pathogenesis of SLE,but DNase1L3 with high activity is not available.To obtain DNase1L3 with satisfactory activity and study its role in the pathogenesis of SLE,we cloned the DNase1L3 molecule and screened out eukaryotic cell lines that steadily express DNase1L3.In order to detect DNase1L3 activity in normal individuals and SLE patients and the correlation between serum DNase1L3 activity level and clinical indexes in SLE patients,we selected 80 SLE patients as the SLE group and 34 healthy volunteers as the control group.We demonstrated that serum DNase1L3 activity in SLE patients[(97.94±0.19)%]was significantly lower than that in the normal individuals[(98.91±0.09)%,P<0.05].Although no significant correlation between serum DNase1L3 activity and anti-nucleosome antibody and anti-dsDNA antibody was found,amid the cohort whose DNase1L3 activity was lower than 98%,serum DNase1L3 activity showed a remarkable negative correlation with anti-nucleosome antibody.Our study suggests that serum DNase1L3 activity level is associated with SLE disease activity and DNase1L3 could have a potential protecting role in the pathogenesis of SLE.